Tarsus Current Deferred Revenue from 2010 to 2024
| TARS Stock | USD 48.24 1.84 3.97% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 627.3 K | Current Value 557.6 K | Quarterly Volatility 39.1 K |
Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 6.8 M or Depreciation And Amortization of 529.3 K, as well as many indicators such as Price To Sales Ratio of 35.81, Dividend Yield of 0.0 or PTB Ratio of 3.17. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.
Tarsus | Current Deferred Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.